Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression

Phase 2

Completed

Conditions: Depression

Interventions: Device: Reclaim™ DBS System

Registration Number: NCT00837486

Lead Sponsor: MedtronicNeuro

Brief Summary: Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression. Depression is a mood disorder and a serious medical condition that affects millions of Americans. Depressive symptoms may include loss of interest in things typically enjoyed; decreased energy levels; difficulty concentrating or making decisions; restlessness; and feelings of pessimism, hopelessness, and worthlessness. Treatment-resistant depression is a chronic and severe form of depression characterized by failure to respond to traditional forms of treatment, such as antidepressant medications and electroconvulsive therapy. Treatment-resistant depression significantly impacts quality of life, productivity, and is a major contributor of disability world-wide.

This randomized, double-blind, sham stimulation-controlled, multi-center, prospective, parallel design study used deep brain stimulation technology to test whether active bilateral stimulation can safely and effectively improve depressive symptoms in patients with treatment-resistant depression compared to sham stimulation.

Participants meeting criteria for the study were implanted with the Reclaim DBS System. Participants in the active group, who received active stimulation, were compared to the control group, who received sham stimulation, during the 16-week blinded-treatment phase. All participants were monitored for changes in depressive symptoms. After the blinded-treatment phase, all participants received active stimulation.

Candidates for the trial were adults who had major depressive disorder and had not responded to several treatments for depression. Participants in the study continued to receive their current antidepressant medications while participating in the trial.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 30

Inclusion Criteria

Consent to participate in screening and study procedures by signing and dating the Informed Consent Form
Are diagnosed with major depressive disorder (MDD)
Have tried at least 4 different treatments, for example antidepressant medications, combinations of antidepressant medications, and/or electroconvulsive therapy (ECT)
Screening MADRS score ≥ 28
Have had the current major depressive episode persist for at least 2 years
Females, if of child-bearing potential, must be using an acceptable method of birth control

Exclusion Criteria

Females: Currently pregnant
Currently enrolled in or plan to enroll in any concurrent drug and/or device study that may confound the results of this study
Have a neurological condition that may jeopardize the safety or the conduct of the study
Have any medical conditions unsuitable for undergoing DBS surgery

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group - Sham Stimulation	Reclaim™ DBS System	Receive sham stimulation with Reclaim™ DBS System
Active Group - Active Stimulation	Reclaim™ DBS System	Receive active stimulation with Reclaim™ DBS System

Primary Outcome Measures

Name	Time	Method
Responders	Baseline to 16 weeks	Montgomery-Åsberg Depression Rating Scale (MADRS); total score can range from 0 (no symptoms) to 60 (severe depression). Response is defined as at least a 50% improvement (decline) in MADRS score. Responder rate is the proportion of participants who experience response.

Secondary Outcome Measures

Name	Time	Method
Depression Change	Baseline to 16 weeks	Montgomery-Åsberg Depression Rating Scale (MADRS); total score can range from 0 (no symptoms) to 60 (severe depression). Improvement is measured by the groups' mean percent change in MADRS score. An improvement is represented by a decline in MADRS (a negative percent change).
Quality of Life Change	Baseline to 16 weeks	Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF); total score can range from 0 to 100 with higher scores indicating a better quality of life. Improvement is measured by the groups' mean change in Q-LES-Q-SF score. An improvement is represented by an increase in Q-LES-Q-SF (a positive change).

Trial Locations

Locations (5): Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Massachusetts General Hospital
🇺🇸
Charlestown, Massachusetts, United States
University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
Butler Hospital
🇺🇸
Providence, Rhode Island, United States
University of Pittsburgh Medical Center
🇺🇸
Pittsburgh, Pennsylvania, United States